全文获取类型
收费全文 | 57篇 |
免费 | 0篇 |
专业分类
儿科学 | 4篇 |
口腔科学 | 2篇 |
临床医学 | 4篇 |
内科学 | 12篇 |
皮肤病学 | 1篇 |
神经病学 | 2篇 |
特种医学 | 2篇 |
外科学 | 2篇 |
药学 | 3篇 |
肿瘤学 | 25篇 |
出版年
2021年 | 2篇 |
2018年 | 1篇 |
2013年 | 2篇 |
2011年 | 3篇 |
2009年 | 1篇 |
2008年 | 3篇 |
2007年 | 3篇 |
2006年 | 3篇 |
2005年 | 4篇 |
2004年 | 3篇 |
2002年 | 5篇 |
2000年 | 1篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1994年 | 2篇 |
1993年 | 2篇 |
1992年 | 2篇 |
1991年 | 5篇 |
1990年 | 2篇 |
1989年 | 5篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有57条查询结果,搜索用时 15 毫秒
1.
S J Vukelja W J Baker P Jeffreys B A Reeb T Pick 《American journal of clinical oncology》1992,15(6):500-502
Nonbacterial thrombotic endocarditis is an uncommon, but well-described, complication of bone marrow transplantation. We describe a case of nonbacterial thrombotic endocarditis following autologous bone marrow transplantation that was marked by weight gain, hepatomegaly, ascites, and extreme hyperbilirubinemia leading to a clinical diagnosis of hepatic veno-occlusive disease. Autopsy revealed nonbacterial thrombotic endocarditis of the tricuspid and pulmonic valves, and passive congestion of the liver, but there was no evidence of veno-occlusive disease. We discuss the pathophysiology and clinical features of nonbacterial thrombotic endocarditis and review its occurrence in association with bone marrow transplantation. Nonbacterial thrombotic endocarditis is often difficult to detect clinically and should be a diagnostic consideration in patients who develop systemic emboli or congestive heart failure after bone marrow transplantation. 相似文献
2.
O'Shaughnessy JA Vukelja SJ Holmes FA Savin M Jones M Royall D George M Von Hoff D 《Clinical breast cancer》2005,5(6):439-446
Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy. This randomized, double-blind, placebo-controlled pilot trial assessed the feasibility of quantifying the effects of epoetin alfa on cognitive function and mood, and evaluated its effects on fatigue and QOL in patients with breast cancer treated with anthracycline-based adjuvant or neoadjuvant chemotherapy. Patients were randomized to receive epoetin alfa 40,000 U subcutaneously once weekly or placebo at the beginning of 4 cycles of chemotherapy administered over 12 weeks. Cognitive function was assessed by Executive Interview (EXIT25) and Clock Drawing Tasks; mood by Profile of Mood States; anemia-related symptoms, including fatigue, by the Functional Assessment of Cancer Therapy-Anemia (FACT-An) subscale; and QOL by Linear Analog Scale Assessment. Ninety-four patients were evaluable for efficacy and safety. Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3; the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function). There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment. Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy. Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo. Epoetin alfa therapy was well tolerated. These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy. 相似文献
3.
4.
5.
Our patient had stage IIIAI Hodgkin's disease with synchronous myelofibrosis and myeloid metaplasia. A slowly progressive myeloproliferative disease developed over 9 1/2 years and terminated in a painful osteolytic bone disease, spinal extradural granulocytic sarcoma and acute megakaryocytic leukemia. It is likely that this was a result of the myeloproliferative disease rather than a late complication from combination chemotherapy. Our case demonstrates the importance of a curative approach to Hodgkin's disease even in the face of a coexistent disease with a long or unknown natural history. 相似文献
6.
C Casey Cunningham Sunil Chada James A Merritt Alex Tong Neil Senzer Yuan Zhang Abner Mhashilkar Karen Parker Sasha Vukelja Don Richards Jill Hood Keith Coffee John Nemunaitis 《Molecular therapy》2005,11(1):149-159
The melanoma differentiation-associated gene-7 (mda-7; approved gene symbol IL24) is a tumor suppressor gene whose expression induces selective apoptosis in tumor cells. To characterize the safety and biologic activity of mda-7 gene transfer, we conducted a phase I trial using intratumoral injections of an adenovirus containing the mda-7 construct (Ad-mda7; INGN 241; 2 x 10(10) to 2 x 10(12) vp) in 28 patients with resectable solid tumors. One hundred percent of injected lesions demonstrated INGN 241 vector transduction, transgenic mRNA, elevated MDA-7 protein, and apoptosis induction, with the highest levels near the injection site. Apoptosis of cells in injected tumors was consistently observed even in heavily pretreated patients. INGN 241 vector DNA and mRNA were detected more than 1 cm from the injection site, whereas MDA-7 protein and bioactivity were more widely distributed. Toxicity attributable to the injections was self-limiting and generally mild; however, one patient experienced a grade 3 SAE possibly related to the study drug. Evidence of clinical activity was found in 44% of lesions with the repeat injection schedule, including complete and partial responses in two melanoma patients. Thus intratumoral administration of INGN 241 is well tolerated, induces apoptosis in a large percentage of tumor cells, and demonstrates evidence of clinically significant activity. 相似文献
7.
Although it is well recognized that patients with cobalamin (vitamin B-12) deficiency can develop neuropsychiatric problems, primary care physicians do not frequently realize that patients presenting with only vague neurologic complaints can have vitamin B-12 deficiency as the etiology. During a 1-year period, six patients presented to the Neurology Clinic at Brooke Army Medical Center, Fort Sam Houston, Texas, after evaluation at the primary care level for their neurologic complaints. All six had cobalamin deficiency, and none were anemic. Military primary care physicians should be aware of the various neurologic presentations of these patients. 相似文献
8.
Cynthia Osborne Jagathi D. Challagalla Charles F. Eisenbeis Frankie Ann Holmes Marcus A. Neubauer Nicholas W. Koutrelakos Carlos A. Taboada Sasha J. Vukelja Sharon T. Wilks Mary Ann Allison Praveen Reddy Scot Sedlacek Yunfei Wang Lina Asmar Joyce O’Shaughnessy 《Clinical breast cancer》2018,18(1):e89-e95
Background
Hormonal therapies and single-agent sequential chemotherapeutic regimens are the standards of care for HER2? metastatic breast cancer (MBC). However, treating patients with hormone-refractory and triple negative (TN) MBC remains challenging. We report the results of combined ixabepilone and carboplatin in a single-arm phase II trial.Patients and Methods
In the present prospective analysis of hormone receptor-positive (HR+)/HER2? and TN MBC cohorts, patients could have received 0 to 2 chemotherapy regimens for MBC before enrollment. All patients received ixabepilone 20 mg/m2 and carboplatin (area under the curve, 2.5) on days 1 and 8 every 21 days. The primary endpoint was the objective response rate (ORR). The secondary objectives included progression-free survival (PFS), clinical benefit rate (CBR), overall survival (OS), and toxicity.Results
We enrolled 54 HR+ and 49 TN patients (median, 1 previous chemotherapy regimen for metastatic disease; most in addition to adjuvant chemotherapy). The ORR was 34% and 30.4% for the HR+ and TN patients, respectively, with a corresponding CBR of 56.6% and 41.3%. The ORRs were similar in taxane-pretreated patients (ORR, 31.4% and 28.6% for HR+ and TN patients, respectively). The median OS was 17.9 months for HR+ patients and 12.5 months for TN patients. The median PFS was similar for both groups at 7.6 months. Grade 3/4 nonhematologic toxicities included neuropathy (9%) and fatigue (8%). Nine patients developed grade 3/4 neuropathy, 7 of whom had received previous taxane treatment.Conclusion
Ixabepilone plus carboplatin is active even in later-line HR+ and TN disease. Toxicities were manageable without cumulative myelosuppression. This combination is a reasonable option for those patients with MBC who require combination chemotherapy. 相似文献9.
Donald A. Richards David Loesch Svetislava J. Vukelja Hillary Wu William J. Hyman Jeffery Nieves Yunfei Wang Simin Hu Oluwatoyin O. Shonukan Datchen F. Tai 《Investigational new drugs》2011,29(5):963-970
Purpose: Pemetrexed and pegylated liposomal doxorubicin (PLD) are clinically active as single agents and preclinically synergistic.
This phase I, open-label trial evaluated the maximum tolerated dose (MTD) and safety of pemetrexed followed by PLD in patients
with breast or gynecologic cancers. Patients: Using 3 + 3 dose escalation, cohorts of 3–9 patients received escalating doses of pemetrexed 400–500 mg/m2 on days 1 and 15 and PLD 30–45 mg/m2 on day 1 of a 28-day cycle. All patients received folic acid and vitamin B12 until 21 days after last pemetrexed dose. Patients continued until dose-limiting toxicity (DLT) or progression (PD). Results: From 11/05 to 2/08, 29 patients entered treatment; median age: 60.6 years (range, 47.5–80.1); ECOG PS 0/1: 27.6%/72.4%;
primary disease site: ovarian (55.2%), breast (34.5%), peritoneum (10.3%); prior therapies: chemotherapy (100.0%), surgery
(72.4%), hormones/biologics (35%), and radiation (20.7%). Pemetrexed/PLD dose levels: L1 = 400/30 (n = 4), L2 = 400/35 (n = 6), L3 = 500/35 (n = 9), L4 = 500/40 (n = 7), and L5 = 500/45 (n = 3). Treatment-related grade 3-4 toxicities: hematologic—neutropenia (86.2%), leukopenia (58.6%), thrombocytopenia (48.3%),
anemia (41.4%); nonhematologic—mucosal inflammation (24.1%), febrile neutropenia (24.1%), hand-foot syndrome (13.8%), hypokalaemia
(10.3%). Reasons for discontinuation: PD (48.3%), toxicity (27.6%), patient request (13.8%), and investigator request (10.3%).
Efficacy: 5 ovarian patients (20.8%) achieved partial response; median time to progression (TTP) was 6.1 months (range, 1.2–12.5).
Conclusion: Pemetrexed plus PLD was reasonably tolerated in this heavily–pretreated population. MTD: pemetrexed 500 mg/m2 and PLD 40 mg/m2 may be carried forward to phase II studies in specific patient populations. TTP in platinum-refractory ovarian patients was
greater than expected. 相似文献
10.
Bosnjak A Vućićević-Boras V Miletić I Bozić D Vukelja M 《Journal of oral rehabilitation》2002,29(9):902-905
Recognition and elimination of an oral habit is of utmost importance in the treatment of periodontal disease. It is not probable that the influence of such a factor can lead to the alteration of gingival dimension, but a cofactor role of oral habits in the development of gingival recession has been acclaimed. The purpose of this study was to present cross-sectional data from an epidemiological study performed in two urban settlements in Zagreb, Croatia. The study was performed in 1025 children, in an attempt to try and discover the incidence of oral habits in children with mixed dentition, aged from 6 to 11 years. About 33.37% of the screened population exhibited oral habits, such as nail and object biting, non-nutritive sucking, simple tongue thrusting and lip or cheek biting. Chi-square test analysis showed no statistically significant differences between sex and age groups, a result that does not exclude the oral habits from aetiology of the periodontal pathology. We can conclude that oral habits are a frequent finding, although the cause relation to periodontitis has yet to be cleared completely. 相似文献